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Background: Breast cancer is a heterogeneous disease that can be classified into one of 4 main molecular
sub-types: luminal A, luminal B, Her2 over-expressing and basal-like (BL). These tumour sub-types require different
treatments and have different risks of disease progression. BL cancers can be considered a sub-group of Triple
negative (TN) cancers since they lack estrogen (ER), progesterone (PR) and Her2 expression. No targeted treatment
currently exists for TN/BL cancers. Thus it is important to identify potential therapeutic targets and describe their
relationship with established prognostic factors. Focal adhesion kinase (FAK) is upregulated in several human
cancers and also plays a functional role in tumour angiogenesis. However, the association between breast cancer
sub-types and tumour endothelial-FAK expression is unknown.
Methods: Using immunofluorescence, we quantified FAK expression in tumour endothelial and tumour cell
compartments in 149 invasive breast carcinomas and correlated expression with clinical, pathological and molecular
parameters.
Results: Low endothelial-FAK expression was independently associated with luminal A tumours at univariate
(p < 0.001) and multivariate (p = 0.001) analysis. There was a positive correlation between FAK expression in the
vascular and tumour cell compartments (Spearman’s correlation co-efficient = 0.394, p < 0.001). Additionally,
endothelial and tumour cell FAK expression were significantly increased in TN tumours (p = 0.043 and p = 0.033
respectively), in tumours with negative ER and PR status, and in high grade tumours at univariate analysis.
Conclusion: Our findings establish a relationship between endothelial-FAK expression levels and the molecular
sub-type of invasive breast cancer, and suggest that endothelial-FAK expression is potentially more clinically relevant
than tumour cell FAK expression in breast cancer.
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Breast cancer is a heterogeneous disease which, according
to extensive gene expression profiling, can be grouped into
4 major categories: luminal A, luminal B, human epider-
mal growth factor receptor-2 oncogene (also called Her2/
ERBB2) type and basal-like breast cancer [1,2]. Each
tumour type requires different treatment, has a different
risk of disease progression and distinct patterns of metas-
tasis [3]. Therefore, ER tumours are treated using anti-
estrogen based therapies such as tamoxifen or aromatase
inhibitors and Her2 over-expressing tumours can be
targeted with the anti-Her2 therapy trastuzumab. The
aggressive basal-like (BL) tumours can be considered a
sub-group of triple negative (TN) tumours since most
are negative for ER, PR and Her2 [4,5]. TN/BL cancers
have a poor prognosis in comparison to other molecular
sub-types and targeted molecular therapies are not cur-
rently available for patients with these tumours. Thus
identifying new therapeutic targets becomes a priority
for TN/BL cancers.
Focal adhesion kinase (FAK) is a 125 kDa non-receptor
tyrosine kinase that can be activated both by integrins and
extracellular stimuli such as growth factors [6,7]. FAK is
involved in, and regulates, several key cell processes in
cancer progression and tumour angiogenesis including cell
survival and apoptosis, adhesion, migration and invasion.
In human cancers, increased tumour cell FAK expres-
sion has been shown in several cancer types including
lung, cervical, colon and breast when compared to normal
tissue [8-12]. In non-small–cell lung cancer high tumour
cell FAK expression was found to correlate with increased
lymph node metastasis and decreased survival [8]. Other
studies have shown that cancer cell FAK expression and
activation are linked with malignant transformation but
not with an invasive phenotype in breast carcinomas [13].
Interestingly, endothelial-FAK expression in astrocytic
tumours was increased in higher grade tumours [14].
Understanding the in vivo role of FAK has been aided
by genetic ablation studies in mice. Loss of epidermal
FAK can reduce tumour progression [15]. Additionally,
endothelial specific FAK-kinase domain inactivation is
associated with reduced vascular leakage [16]. Moreover,
endothelial-FAK deletion has been shown to inhibit
tumour growth due to a defect in tumour angiogenesis
initiation [17]. In contrast, FAK-heterozygous mice, that
have half the normal levels of FAK, display elevated
xenograft tumour growth [18]. Together these results
suggest that endothelial-FAK levels may affect tumour
size. Despite these studies no data is available presently
to link endothelial-FAK levels with prognostic factors in
human breast cancer.
The increased expression of FAK in many cancer types
has stimulated the development of FAK inhibitors for
the treatment of cancer [19]. Given the critical role ofthis molecule in both the tumour and endothelial cell
compartment, an analysis of the relationship between
expression and clinicopathological factors would be
beneficial in the design of future clinical trials targeting
FAK.
The purpose of this study was to determine whether
FAK expression in the endothelial cell or tumour cell
compartment of invasive breast carcinomas correlates
with established clinicopathological characteristics, or
differences between molecular sub-types.Methods
Tissue specimens
Formalin-fixed and paraffin-embedded blocks of surgically
resected invasive breast cancers from 149 patients were
provided by the Barts Cancer Institute Breast Tissue Bank,
following informed patient consent (ethics ref:10/H0308/
49). The clinicopathological characteristics (age at presen-
tation, tumour size, tumour grade, lymph node status, and
ER/PR/Her2 status) were obtained from the diagnostic
histopathology reports. The tumours were allocated into
molecular sub-types using the following biomarker profile:
‘luminal A’ (ER and/or PR+, Her2–), ‘luminal B’ (ER and/
or PR+, Her2+), ‘Her2-positive’ (ER–, PR–, Her2+) and
‘triple negative’ (ER–, PR–, Her2–) [20]. This study
followed REMARK guidelines for tumour marker prog-
nostic studies [21].Immunofluorescence analysis
Sections were dewaxed in xylene and blocked in 3%
H2O2 solution in methanol to block endogenous peroxi-
dases. Antigen retrieval was performed by heating sec-
tions in 10 mM Sodium Citrate buffer. Samples were
then blocked with protein block/serum free (Dako,
Cambridgeshire, UK) and incubated with anti-FAK clone
4.47 (Millipore, Massachusetts, USA) and anti-PECAM
antibodies (Millipore) overnight at 4˚C. Mouse and rabbit
IgGs (Dako) were used as a negative control for the anti-
FAK and anti-PECAM antibodies. After incubation with
the primary antibodies, tissue sections were washed three
times in PBS followed by 60 minutes incubation at room
temperature with anti-mouse biotinylated and anti-rabbit
Alexa 546 (Invitrogen Molecular Probes, Paisley, UK)
antibodies. After washing with PBS, tissue sections were
incubated with streptavidin-HRP for 30 minutes at room
temperature (TSA/fluorescein systems; PerkinElmer,
Massachusetts, USA). They were then washed with PBS
and incubated for 5 minutes at room temperature with
Fluorescein Tyramide solution (TSA/fluorescein systems).
The sections were mounted using Prolong Gold Antifade
reagent with DAPI (Invitrogen Molecular Probes, Paisley,
UK). Fluorescence was analysed using the epifluorescent
Zeiss Axioplan Microscope (Carl Zeiss, Germany).
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For each case, images covering 75% to 100% of the tissue
section were acquired. Each image was scored for FAK
expression in tumour cells based on a scoring system
that measured both percentage of positive cells (0, none;
1, <25%; 2, 25-50%; 3, 50-75%; 4, >75%) and intensity of
staining (0, none; 1, weak; 2, moderate; 3, strong). The
sum of these values provided a score ranging from 0–7
for each image. A mean score was then calculated for
each case. In addition, each image was scored for FAK
expression in tumour endothelium based on a scoring
system that measured the intensity of FAK staining in
each vessel (0, none; 1, borderline; 2, weak; 4, moderate;
6, strong) and took into account the percentage of posi-
tive cells per vessel. If <20% of the endothelial cells in a
vessel were positive for FAK this vessel was assigned half
of the intensity value of the positive cells. This system
provided possible outcomes of 7 categories (0, 0.5, 1, 2,
3, 4, 6) for each blood vessel of every case. The intensity
of staining was multiplied by the percentage of vessels
with that score. These values were then summed to give a
total score for all vessels ranging from 0 to 600. The ves-
sels analysed had a diameter ≥5 μm and were <100 μm
distance from tumour cells. The median number of vessels
scored per case was 44. The samples were scored by one
person in a blinded manner. To validate the score for FAK
expression, 10 tumour samples were stained and scored
twice on different days, providing similar scores.Statistical analysis
FAK expression scores for both tumour cells and blood
vessels were considered as non-parametric continuous
variables since neither follows a normal distribution.
The correlation between FAK expression and continuous
variables was performed using Spearman’s correlation
co-efficient and the Mann–Whitney U test was per-
formed to assess possible associations between FAK
expression and categorical variables. The correlation
between FAK expression and molecular sub-type was
carried out using univariate and multivariate logistic
regression with forward step-wise entry. In the regres-
sion analysis, to facilitate comparison between tumour
cell and endothelial cell FAK, scores were re-scaled to
give a score between 0 and 1. Scores were re-scaled by
dividing the parameter score by its maximum value, so
for example a raw score of 600 would be rescaled to
600/600 = 1. Alternatively, a score of 200 would be
rescaled to 200/600 = 0.33. A two-sided p-value less than
0.05 was considered statistically significant. Statistical
analyses were performed with SPSS statistical software,
Version 19.0 (IBM Corp., Armonk, New York, USA)
and GraphPad Prism, Version 4.0 (GraphPad Software
Inc., La Jolla, CA, USA).Results
Patient and tumour characteristics
Of the 149 patients included in this study, 129 had inva-
sive ductal carcinoma, no special type, 15 had invasive
lobular carcinoma, 2 had invasive micropapillary carcin-
oma and there was one patient each with mucinous,
metaplastic and apocrine carcinoma. The mean age at
presentation was 56.6 years and the mean tumour size
was 26.6 mm. Grade 3 tumours accounted for 61% of
the cohort and 48% of the patients had lymph node in-
volvement. The luminal A sub-type was the most com-
mon, accounting for 38% of tumours. The percentage of
tumours with positive ER, PR and Her2 status was 58%,
53% and 8% respectively. The clinicopathological features
of the cohort are summarized in Table 1.
Correlation between endothelial and tumour cell FAK
expression
There was a positive correlation between FAK expres-
sion in the vascular and tumour cell compartments
(Spearman’s correlation co-efficient = 0.394, p < 0.001).
Representative immunofluorescent images of FAK ex-
pression in the tumour endothelial and cancer cell com-
partments in luminal A (Figure 1A–D), luminal B
(Figure 1E–H), Her2-overexpressing (Figure 1I–L) and
Triple Negative (Figure 1M–P) invasive breast carcinomas
are shown in Figure 1. Additional file 1 shows images of
tissue incubated with isotype control antibodies.
Tumour endothelial-FAK expression and relation with
clinicopathological factors
There was no significant correlation between endothelial-
FAK expression and patient age at presentation or tumour
size (Table 2). Significantly higher mean endothelial FAK
scores were seen in grade 3 tumours (p = 0.008), ER nega-
tive tumours (p = 0.005), PR negative tumours (p = 0.002)
and Her2 positive tumours (p = 0.022, Table 3). Endothelial-
FAK expression was higher in TN versus non-TN tumours
(p = 0.043) and lower in luminal A versus non-luminal A
tumours (p < 0.001, Table 3). There were no significant dif-
ferences in endothelial-FAK levels in primary tumours be-
tween lymph node positive and lymph node negative
tumours, or between luminal B versus non-luminal B and
Her2 positive versus non-Her2 positive sub-types, although
the highest FAK scores were seen in the Her2 positive sub-
type (Table 3).
FAK expression in tumour cells in relation to
clinicopathological factors
There was no significant correlation between tumour cell
FAK expression and patient age at presentation or tumour
size (Table 2). Significantly higher mean cancer cell FAK
scores were seen in grade 3 tumours (p = 0.001), ER-
negative tumours (p = 0.013) and PR-negative tumours
Table 1 Clinical, pathological and molecular features of
the patient cohort
Parameter N Mean (95% CI)/
Percentage of cases (%)
Age 148 56.6 years (54.5-58.6)
Tumour size 149 26.6 mm (23.8-29.3)
Tumour grade 149
1 2 1
2 56 38
3 91 61
Lymph node involvement 145
Yes 69 48
No 76 52
ER status 149
Positive 87 58
Negative 62 42
PR status 149
Positive 79 53
Negative 70 47
Her2 status 149
Positive 12 8
Negative 137 92
Molecular sub-type 149
Luminal A 56 38
Luminal B 31 21
Her2 positive 12 8
TN 50 33
Abbreviations; CI = confidence interval, ER = estrogen receptor,
PR = progesterone receptor, TN = triple negative.
Alexopoulou et al. BMC Cancer 2014, 14:237 Page 4 of 8
http://www.biomedcentral.com/1471-2407/14/237(p = 0.048, Table 3). Tumour cell FAK expression was
significantly higher in TN versus non-TN tumours
(p = 0.033) and lower in luminal A versus non-luminal A
tumours (p = 0.001, Table 3). There was no significant
difference in cancer cell FAK scores between tumours
with and without lymph node involvement or between
tumours with positive and negative Her2 status. As with
endothelial-FAK expression, there was no significant
difference between the luminal B versus non-luminal B
and Her2 versus non-Her2 molecular sub-types although
again, the Her2 positive sub-type had the highest absolute
FAK score (Table 3).
Correlation of FAK expression and established prognostic
factors with the Luminal A sub-type – univariate
regression
Given that the strongest statistical association in the
sub-type analysis for both endothelial and tumour cell
FAK expression was with lower scores in the luminal A
versus non-luminal A tumours, we performed univariate
regression analysis to identify other parameters thatassociated with luminal A tumours (Table 4). The 3 pa-
rameters that showed a significant association with lu-
minal A tumours were tumour grade (p < 0.001), FAK
expression in tumour cells (p = 0.001) and FAK expression
in endothelial cells (p < 0.001). These three factors had an
odds ratio below 1, confirming the association between
low grade (grade 1/2) and low FAK expression in the
luminal A sub-type (Table 4).
Independent correlation of endothelial-FAK with the
Luminal A sub-type
To establish whether low endothelial-FAK expression was
independently associated with luminal A tumours, we per-
formed multivariate logistic regression. The parameters
that associated with luminal A tumours at univariate
analysis (tumour grade, endothelial-FAK expression and
tumour cell FAK expression) were placed into the
model in a step-wise fashion. The 2 parameters that
remained in the model were tumour grade (OR 0.14,
95% CI: 0.07-0.31; p < 0.001) and endothelial-FAK expres-
sion (OR 0.03, 95% CI: 0.01-0.25; p = 0.001, Table 5),
suggesting that low endothelial-FAK expression is inde-
pendently associated with the luminal A sub-type, even
after taking tumour grade into account.
Discussion
The aim of the current study was to determine whether
the levels of endothelial and tumour cell FAK correlate
with clinicopathological characteristics in invasive breast
carcinoma. While low expression of both endothelial and
tumour cell FAK associated with luminal A tumours, only
endothelial-FAK was independently associated with these
tumours in multivariate analysis. This is the first study to
demonstrate a relationship between endothelial-FAK ex-
pression and molecular sub-type in invasive breast cancer
and our findings suggest that vascular expression of FAK
is potentially more clinically relevant than tumour cell
FAK in breast cancer.
The importance of FAK in angiogenesis and in cancer
progression has been shown in several animal studies
[15,17,18,22-24]. These studies in combination with the
observed upregulation of FAK in several epithelial can-
cers has initiated the development of FAK inhibitors for
the treatment of cancer [19].
Previous studies have investigated the significance of
tumour cell FAK expression in invasive breast cancer
[12,25-28]. Few of these studies looked specifically at
molecular sub-type, but Yom et al. found that low
tumour cell FAK expression correlated with the luminal
A sub-type and higher levels with the luminal B and TN
sub-types at univariate analysis [28] and our results
corroborate these findings. In particular our finding of
increased tumour cell and endothelial cell FAK in TN
tumours suggest that FAK likely plays a role in the
Figure 1 Immunofluorescence Analysis of FAK expression in invasive breast tumour epithelium and endothelium of different ‘Intrinsic’
molecular tumour types. Formalin fixed paraffin embedded tissue was stained for Pecam-1 (red) to identify endothelial cells and for FAK (green).
Cell nuclei have been identified by counterstaining with DAPI. Characteristic examples are shown from Luminal A (A–D), Luminal B (E–H),
Her2-overexrpessing (I–L) and Triple Negative (M–P) invasive breast tumours. All images are on x40 magnification. The analysed vessels had a
diameter ≥5 μm and vessels in a ≥100 μm distance away from the tumour cell margins have been excluded. Arrows indicate tumour cells and
arrowheads analysed blood vessels.
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ing molecular sub-type are mirrored by our observations
of the individual steroid receptors and Her2, where in-
creased FAK expression correlated with ER and PR nega-
tivity and Her2 positivity. Others have shown comparableTable 2 Correlation between FAK expression and
prognostic factors (continuous variables)
FAK location Parameter Correlation co-efficient p-value
Vessels Patient age 0.096 0.246
Tumour size 0.089 0.28
Tumour cells Patient age −0.138 0.094
Tumour size 0.119 0.148
Spearman’s correlation co-efficient.findings [12,25,28]. Interestingly, in a study investigating
the relationship between FAK and major signaling path-
ways in 162 node-negative breast cancers, elevated FAK
expression correlated with Her2 over-expression and
phospho-Src Tyr-215, prompting the authors to speculate
that the activation of Akt via the FAK pathway contributes
to the aggressive nature of Her2 over-expressing tumours
[12]. Although we didn’t find a statistically significant
increase in endothelial/tumour cell FAK in the Her2
positive/luminal B sub-types (versus non-Her2 positive/
non-luminal B tumours) the absolute scores were higher
in the former and the lack of significance may reflect
the smaller patient numbers in these groups.
We found higher FAK expression (endothelial and tumour
cell) in more aggressive grade 3 tumours, compared to
Table 3 Association between FAK expression and
prognostic factors (categorical variables)
FAK
location
Parameter Mean FAK score
(95% CI)
p-value
Vessels Tumour grade
1 or 2 156.2 (124.6-187.8)
3 200.2 (177.9-222.6) 0.008
Lymph node
involvement
Yes 184.7 (157.7-211.7)
No 179.6 (152.8-206.5) 0.765
ER status
Positive 161.3 (139.9-184.6)
Negative 213.7 (184.7-242.7) 0.005
PR status
Positive 156.8 (131.6-181.9)
Negative 212.8 (186.7-238.9) 0.002
Her2 status
Positive 215.8 (181.6-250.0)
Negative 169.8 (148.0-191.6) 0.022
Molecular sub-type
Luminal A vs
Non-Luminal A
135.4 (107.6-163.2) vs
211.8 (189.0-234.6)
<0.001
Luminal B vs
Non-Luminal B
208.0 (169.1-246.9) vs
176.5 (155.5-196.6)
0.130
Her2 positive vs
Non-Her2
235.9 (155.8-316) vs
178.5 (159.5-197.4)
0.121
TN versus Non-TN 208.4 (176.6-240.1) vs
170.3 (147.6-193.0)
0.043
Tumour
cells
Tumour grade
1 or 2 4.1 (3.6-4.7)
3 5.1 (4.8-5.5) 0.001
Lymph node
involvement
Yes 5.1 (4.7-5.4)
No 4.5 (4.0-5.0) 0.249
ER status
Positive 4.4 (4.0-4.9)
Negative 5.2 (4.8-5.6) 0.013
PR status
Positive 4.4 (4.0-4.9)
Negative 5.1 (4.7-5.5) 0.048
Her2 status
Positive 5.1 (4.6-5.6)
Negative 4.6 (4.2-5.0) 0.215
Molecular sub-type
Luminal A vs
Non-Luminal A
4.1 (3.5-4.7) vs
5.2 (4.8-5.5)
0.001
Table 3 Association between FAK expression and
prognostic factors (categorical variables) (Continued)
Luminal B vs
Non-Luminal B
5.0 (4.4-5.6) vs
4.7 (4.3-5.0)
0.408
Her2 positive vs
Non-Her2
5.3 (4.5-6.1) vs
4.7 (4.4-5.0)
0.406
TN versus Non-TN 5.2 (4.7-5.7) vs
4.5 (4.1-4.9)
0.033
Significant findings are in italics (Mann–Whitney test). Abbreviations:
CI = confidence interval.
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have evaluated tumour cell FAK expression in tissue
and cytology specimens from invasive breast cancers
[12,25,27,28]. Tumour grade is an established poor prog-
nostic factor in breast cancer [29] and given the associ-
ation between high grade (and other prognostic factors
such as ER/PR negativity) and high FAK expression it is
entirely possible that FAK over-expression is associated
with a poor outcome. To date, studies of outcome in rela-
tion to protein expression of FAK in human breast cancers
have not demonstrated a significant effect on survival
[12,28], and larger studies with long term follow-up are
needed. Of note, FAK amplification/high polysomy has
been shown to be an independent poor prognostic factor
for both overall and relapse-free survival [28].
A previous clinical trial looking at the VEGFR inhibitor,
Sunitinib in unselected breast cancer patients has been
unsuccessful [30]. Given the association between increased
VEGF-receptor 2 expression in TN breast cancer [31], tar-
geting TN breast cancer with Sunitinib or the anti-VEGF
agent Bevacizumab may be a more effective approach and
these clinical trials are now ongoing [30,32]. Likewise, our
results suggest that clinical trials should consider focusing
on non-luminal A tumours in the evaluation of FAK in-
hibitors for the treatment of breast cancer. Moreover,
since the expression of FAK is not limited to a single can-
cer compartment effective inhibition of FAK signaling is
particularly appealing.Table 4 Association between prognostic factors, FAK
expression and the luminal A sub-type
Parameter LR Chi Square OR (95% CI) p-value
Age at diagnosis 11.12 1.01 (0.99-1.04) 0.413
Tumour size 0.05 1.00 (0.98-1.02) 0.823
Tumour grade 32.03 0.13 (0.06-0.27) <0.001
Lymph node status 2.06 0.61 (0.31-1.20) 0.154
FAK tumour cells 11.41 0.11 (0.03-0.42) 0.001
FAK vessels 17.11 0.02 (0.01-014) <0.001
Significant findings are in italics (univariate logistic regression). Abbreviations:
LR = likelihood ratio, OR = odds ratio, CI = confidence interval
Table 5 Multivariate model containing parameters
predictive of the luminal A sub-type
Parameter Stepwise
entry
LR Chi Square OR (95% CI) p-value
Tumour Grade 1 32.03 0.14 (0.07-0.31) <0.001
FAK vessels 2 11.31 0.03 (0.01-0.25) 0.001
Multivariate logistic regression with stepwise forward entry. Abbreviations:
LR = likelihood ratio, OR = odds ratio, CI = confidence interval.
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In conclusion, this study is the first to analyse endothelial-
associated FAK expression in human breast tumour
samples. We demonstrate that lower endothelial FAK
expression is independently associated with the luminal
A sub-type, and conversely, high endothelial and tumour
cell FAK expression correlates with the poorer prognosis
non-luminal A tumours and other established poor prog-
nostic factors. The association between high FAK levels
and TN tumours is worthy of further investigation in a
larger series to establish the prognostic significance of
tumour/endothelial FAK in the TN/BL sub-type. Overall
our findings strengthen the argument for investigating
the role of FAK inhibitors as a novel treatment for poor
prognosis breast cancer sub-types and identify endothe-
lial expression of the protein as a potentially useful bio-
marker for future clinical studies.
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Additional file 1: Negative controls for immunofluorescence
staining. Formalin fixed paraffin embedded IDC tissue was incubated
with rabbit IgG and mouse IgG antibodies, followed by anti-rabbit (Alexa
546; red) and anti-mouse (Alexa-488; green) secondary antibodies. Cell
nuclei have been identified by counterstaining with DAPI.
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